



















Mirabegron, a clinically approved β3 adrenergic 
receptor agonist, does not reduce infarct size in a swine 
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AMI   acute myocardial infarction 
β3AR    β3 adrenergic receptor 
CMR   cardiovascular magnetic resonance 
IRI   ischemia/reperfusion injury 
IS   infarct size 
LV   left ventricle 
LVEDV   left ventricular end-diastolic volume 
LVEF   left ventricular ejection fraction  
LVESV   left ventricular end-systolic volume 





The administration of the selective β3 adrenergic-receptor (β3AR) agonist BRL-37344 protects 
from myocardial ischemia/reperfusion injury (IRI), although the lack of clinical approval limits 
its translatability. We tested the cardioprotective effect of mirabegron, the first-in-class β3AR 
agonist approved for human use. A dose-response study was conducted in 6 pigs to select the 
highest intravenous dose of mirabegron without significant detrimental hemodynamic effect. 
Subsequently, closed-chest anterior myocardial infarction (45min ischemia followed by 
reperfusion) was performed in 26 pigs which randomly received either mirabegron (10µg/kg) or 
placebo 5min before reperfusion. Day-7 cardiac magnetic resonance (CMR) showed no 
differences in infarct size (35.0±2.0% of left ventricle (LV) vs. 35.9±2.4% in mirabegron and 
placebo respectively, p=0.782) or LV ejection fraction (36.3±1.1% vs. 34.6±1.9%, p=0.430). 
Consistent results were obtained on day-45 CMR. In conclusion, the intravenous administration 
of the clinically available selective β3AR agonist mirabegron does not reduce infarct size in a 
swine model of IRI.  
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Acute myocardial infarction (AMI) is a leading cause of mortality and morbidity 
worldwide [1, 2]. Early coronary reperfusion limits myocardial infarct size (IS), which is the 
main prognostic determinant in post-AMI patients [3]. Paradoxically, reperfusion itself induces 
additional damage to the myocardium, known as ischemia/reperfusion injury (IRI) [4]. Beyond 
timely reperfusion, further IS-limiting therapies targeting the myocardial injury that occurs after 
ischemia/reperfusion are needed to further improve clinical outcomes [5].  
The β3 adrenergic-receptor (β3AR) is a G-protein-coupled receptor preferentially 
expressed in adipose tissue that has been raising interest as a cardiovascular target due to its 
expression in human cardiomyocytes and endothelial cells[6], as well as its protective role in 
several cardiovascular diseases [7]. The administration of the β3AR agonist BRL-37344 either 5 
min before or at the onset of reperfusion, has been demonstrated to reduce myocardial IS and 
improve cardiac function both in mouse [8, 9] and swine models of IRI [9]. Also, β3AR 
stimulation has been shown to improve left ventricular (LV) remodeling in small animal models 
of heart failure after non-reperfused MI [10] or pressure overload hypertrophy [11], as well as to 
improve right ventricular performance in a porcine model of chronic pulmonary hypertension 
[12]. Many of these protective effects are mediated through the nitric oxide synthase (NOS), as 
β3AR effects are abrogated with either its pharmacological or genetic inhibition [9, 13]. 
The β3AR agonist (mirabegron) is the first agent of this class clinically approved (in 
Europe, US and Japan) for treating overactive bladder [14]. However, there is no data regarding 
its potential benefit in the context of AMI, based on the principle of “drug repurposing” for a 
new cardiovascular indication. Confirmation of an infarct-limiting effect and long-term 
functional benefits from this new therapeutic strategy in a large animal model would have a 
significant translational impact and should be considered the first step before conducting a 
clinical trial in humans in this setting [15].  
We therefore hypothesized that the β3AR agonist mirabegron may provide a protective 
effect against myocardial IRI, improving both IS and LV function and remodeling. According to 
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this hypothesis, the aims of this study were (1) to assess the effect of the administration of 
mirabegron on hemodynamic parameters in a dose-response fashion and determine the optimal 
intravenous dose to use in subsequent experiments; (2) to investigate whether β3 stimulation 
with mirabegron reduces myocardial IS in a large animal model of IRI; and (3) to elucidate 
whether β3 stimulation with mirabegron improves ventricular remodelling and left ventricular 
ejection fraction (LVEF) in a large animal model of AMI. 
Methods 
Animals and drug 
All animal studies were conducted at the CNIC and approved by the local CNIC 
Institutional Animal Research Committee, and the Regional Animal Research Committee. All 
animal procedures conformed to EU Directive 2010/63EU and Recommendation 2007/526/EC 
regarding the protection of animals used for experimental and other scientific purposes. 
Pharmocokinetics and bioavalability of mirabegron in healthy subjects and animals has been 
described elsewhere [16, 17]. 
Study design 
The study design consisted of two stages, the first to identify the best dose of 
mirabegron, and the second one to assess its cardioprotective effects. In phase one, we 
performed a dose-response evaluation aimed to determine the optimal intravenous dose to be 
uses subsequently in phase two. Four intravenous bolus doses of mirabegron (5, 10, 50 and 500 
µg/Kg) were administered alongside its vehicle (1 ml DMSO + 19 ml of saline) in a group of six 
healthy pigs under close monitoring through electrocardiogram, pulse oximeter, invasive 
systemic blood pressure (SBP) and right heart catheterization. A complete hemodynamic 
evaluation was obtained every minute during the first 5 min and then every 5 min until reaching 
20 min post-drug administration. The highest dose with no significant detrimental 
hemodynamic effects was chosen. No significant detrimental effect was defined as changes in 
hemodynamics of less than 10% with respect the baseline value.  
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In phase two, 26 pigs undergoing IRI (45 minutes coronary artery occlusion followed 
by reperfusion) were randomized to either receive a bolus of intravenous placebo (1 ml of 
DMSO + 19 ml of saline) or intravenous mirabegron (10 µg/kg diluted in 1 ml of DMSO + 19 
ml of saline) over a 30 seconds period at min 40 of ischemia (i.e. 5 minutes prior to 
reperfusion). Cardiac magnetic resonance (CMR) was performed at two time-points: a) day 7; 
and b) day 45, after reperfusion. The pre-defined primary endpoint of the study was IS (% LV 
mass) on day 7 CMR, while the main secondary endpoint was LVEF on day 45 CMR.  
 
Pig model of acute myocardial infarction 
AMI was experimentally induced in 3-month-old castrated male Large-white pigs bred 
at the CNIC’s farm. The protocol for AMI induction has been described in detail elsewhere[18]. 
Briefly, anesthesia was induced by intramuscular injection of ketamine (20 mg/kg), xylazine (2 
mg/kg), and midazolam (0.5 mg/kg), and maintained by continuous intravenous infusion of 
ketamine (2 mg/kg/h), xylazine (0.2 mg/kg/h), and midazolam (0.2 mg/kg/h). The analgesic 
buprenorphine (0.03 mg/kg) was administered by intramuscular injection immediately before 
the procedure. 
Pigs were intubated and mechanically ventilated with oxygen (fraction of inspired O2, 
28%). Central venous and arterial lines were inserted, and a single bolus of unfractionated 
heparin (300 IU/kg) was administered at the onset of the instrumentation. During the procedure, 
a continuous infusion of amiodarone (300 mg/h) was systematically used to avoid malignant 
ventricular arrhythmias. Amiodarone was initiated immediately after coronary artery occlusion. 
The mid-left anterior descending coronary artery (distal to the origin of the first diagonal 
branch) was occluded for 45 min with an angioplasty balloon inserted through percutaneous 
femoral access. After 45 min, the balloon was deflated, and blood flow restoration was 
documented by angiography. Animals were randomly allocated 1:1 to receive either the b3AR 
agonist (mirabegron, 10 µg/kg) or vehicle via marginal vein of the ear 5 min before reperfusion 
(i.e. 40 min after coronary artery occlusion). The treatment (mirabegron or vehicle) was 
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administered by operators blinded to the allocation. During the procedure, invasive 
hemodynamic measurements were obtained as detailed above. After the procedure, both 
veterinarians and technicians at the CNIC Comparative Medicine Unit took care of the recovery 
of the animals. 
CMR protocol 
CMR studies were performed 7 and 45 days after AMI to assess infarct size (% of LV) 
and LV function. On each CMR exam, pigs were anesthetized by intramuscular injection of 
ketamine, xylazine and midazolam as described above, and maintained by continuous 
intravenous infusion of midazolam. All studies were performed using a Philips Achieva 3T-Tx 
whole body scanner (Philips Medical Systems, Best, The Netherlands) equipped with a 32-
element cardiac phased-array surface coil. Images were acquired with the use of 
electrocardiogram gating by operators blinded to the treatment allocation. Segmented cine 
steady-state free precession (SSFP) was performed to acquire 15 contiguous short-axis slices 
covering the heart from the base to the apex to assess LV mass, LV volumes and ejection 
fraction with the following parameters: FOV of 280 x 280 mm; slice thickness of 6 mm without 
gap; TR 2.8 ms; TE 1.4 ms, flip angle 45; cardiac phases 25; voxel size 1.8 x 1.8 mm; 3 NEX. 
Edema imaging was performed using a T2-weighted, triple inversion-recovery fast spin-echo 
(T2W-STIR) sequence with the following parameters: FOV of 300 x 300; 15 short-axis slices 
with thickness of 6 mm and no gap; TR 2 heartbeats; TE 80 ms; voxel size 1.4 x 1.8 mm; STIR 
delay 210 ms;echo-train length 18; 2 NEX. T2W images were corrected by coil sensitivities 
using Constant LEvel AppeaRance (CLEAR) algorithm. To determine myocardial IS, late 
gadolinium enhancement imaging was performed 15 min after the administration of 0.2 
mmol/kg gadopentate dimeglumine using a T1 inversion-recovery spoiled turbo field echo (T1-
IR-TFE) sequence with the following parameters: FOV of 280 x 280 mm; 15 short axis slices 
with a thickness of 6 mm and no gap; TR 3.3 ms; TE 1.6 ms; voxel size 1.8 x 1.8 mm; inversion 
time was optimized to null normal myocardium; 2 NEX. 
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CMR data analysis 
All CMR images were assessed using dedicated software (QMassMRv.7.6, Medis, 
Leiden, The Netherlands). Images were evaluated by 2 experienced observers in CMR analysis, 
blinded to treatment allocation, following a well-established protocol as described 
previously[9]. Briefly, LV cardiac borders were traced in each cine image to obtain LV end-
diastolic mass, LV end-diastolic volume (LVEDV), end-systolic volume (LVESV) and LVEF. 
LV mass and volumes normalized to the body surface area were calculated using the modified 
Brody’s method[19]. The extent of edema, expressed as a percentage of LV mass, was defined 
after manually tracing the endocardial and epicardial contours of T2W-STIR short-axis images. 
IS, expressed as a percentage of LV mass, was defined according the extent of late gadolinium 
enhancement after manually tracing the endocardial and epicardial contours on T1-IR-TFE short 
axis images. Edema and IS were identified as hyperintense regions, defined as >50 % of the 
peak myocardial signal intensity (full width half maximum) with manual adjustment if required. 
When present, hypointense areas within the edematous or necrotic zone were included in the 
edematous or necrotic region for quantification purposes.   
Statistical analysis 
Continuous variables are expressed as mean ± standard deviation. Levene’s robust test 
was performed to check the equality of variances between groups. CMR outcomes were 
compared between treatment groups using the Student's t-test. A generalized mixed model was 
conducted for comparison of heart rate and mean arterial pressure among repeated measures at 
different time points. All pairwise comparisons were explored, adjusting p values for multiple 
comparisons using the Bonferroni method. A P value of less than 0.05 was considered 
statistically significant. STATA software, version 15.1 (Stata Corp, College Station, TX, USA) 




Phase 1: Dose-response study 
To select the highest dose without a relevant (detrimental) hemodynamic effect (<10% 
change in mean systemic blood pressure or heart rate), a dose-response assessment was 
performed in anesthetized pigs using the following doses 5, 10, 50 and 500 µg/Kg. The effect of 
intravenous administration of mirabegron on relevant hemodynamic parameters is presented in 
Table 1. Overall, the two low doses (5 and 10 µg/Kg) had little impact on the hemodynamic 
performance, whilst the two high doses (50 and 500 µg/Kg) resulted in a substantial impact on 
both cardiac output and heart rate. Taking into account these results, a dose of 10 µg/Kg was 
chosen for subsequent experiments. 
Phase 2: Effect of mirabegron in IRI 
Study population  
Twenty-six pigs underwent AMI procedure. One AMI procedure failed, and 5 pigs died 
within the first week after AMI before day7 CMR (3 allocated to placebo and 2 allocated to 
mirabegron). Thus, a total of 20 pigs (n=10/group) underwent CMR at day 7 having the primary 
outcome measured and comprised the final study population. Two of these 20 pigs died between 
day 7 and 45, both belonging to the mirabegron group. During AMI procedure, there were no 
relevant differences in hemodynamic parameters between placebo pigs and those allocated to 
mirabegron (Table 2).  
CMR at day 7 
CMR results at day 7 after AMI by group allocation are detailed in Table 3. At this 
time-point, there were no significant differences in neither infarct size (35.0±2.0%vs. 
35.9±2.4% in mirabegron and placebo respectively, p=0.782) nor in LVEF (36.3±1.1%vs. 
34.6±1.9%, respectively; p=0.430) (Figure 1). Similarly, there were no differences in the 
extension of edema as measured by T2W-STIR between groups (38.0 ± 5.6 % of LV vs. 38.4 ± 
5.9 % of LV, in mirabegron and placebo respectively; p=0.884).  The presence of microvascular 
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obstruction was not different between groups (2.3 ± 1.6 g vs 2.1 ± 1.9 g, in mirabegron and 
placebo respectively; p=0.841). 
 
CMR at day 45 
Consistent results were obtained after 45 days of reperfusion (Table 4). No significant 
differences were observed between groups in neither IS (23.7±6.3% vs 25.2±4.5%, in 
mirabegron and placebo, respectively; p=0.581) nor in LVEF (33.1±5.7% vs. 30.0±7.0%, 
respectively; p=0.366) (Figure 2). No significant differences were observed in LV end-diastolic 
volume (189.6 ± 23.7 ml/m2 vs. 202.9 ± 43.4ml/m2 in mirabegron and placebo respectively; 
p=0.449) and end-systolic volume (127.9 ± 26.7ml/m2 vs. 143.9 ± 43.5 ml/m2 in mirabegron 
and placebo respectively; p=0.377). 
 
Discussion 
β3AR stimulation with mirabegron does not protect the myocardium against IRI in a 
swine model of AMI. To our knowledge, this is the first study demonstrating that the i.v. 
administration of mirabegron fails to confer cardioprotection in a large animal model of IRI. 
Given the previous demonstration of the infarct-limiting effects of other β3AR agonists [8, 9], 
our data suggest a non-class infarct limiting effect of β3AR agonism. 
There is a wealth of evidence demonstrating the cardioprotective effect afforded by 
β3AR agonists when administered during the first minutes of reperfusion [8, 9]. It has been 
suggested that this cardioprotective effect is provided (i) at the myocardial level by a delay in 
mPTP opening dependent on the Akt-NO signaling pathway; and (ii) at the endothelial level by 
the release of NO. These protective effects at the myocardial and endothelial level may be 
reinforced from other effects – i.e. paracrine effect of NO to improve LV relaxation and 
antioxidant effects of β3AR signaling, which may help to preserve microvasculature [7]. 
However, all this previous evidence was based on the β3AR agonist BRL-37344 [8, 9]. 
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Unexpectedly, the administration of mirabegron did not confer protection against IRI in our 
swine model of AMI. This seemingly contradictory results do not necessarily contravene 
previous reports and might be explained by several reasons. 
The most important difference with previous reports lies in the use of different drugs. 
Within high-affinity β3AR agonists, BRL37344 belongs to the phenylethanolamines class and 
mirabegron (YM178) belongs to the aryloxypropanolamines [12]. The latter has the advantage 
of being already approved for human use to treat hyperactive bladder syndrome as well as being 
available in oral tablets [14], which might be useful as a longer treatment to improve post-AMI 
LV remodeling and LVEF [20]. It is known that BRL37344 has a lower affinity for β3AR in 
comparison with mirabegron [21]. Similarly, BRL37344 has a slight effect in other βAR [22], 
which might justify the disagreement in our results. However, BRL37344 did not confer 
cardioprotection in β3AR KO mice [9], thus suggesting a minor role for other β adrenergic 
receptors. 
The second possibility justifying the failed study is the dose of the drug used in the IRI 
experiments. Given the lack of publications in this regard, we chose the mirabegron dose based 
on our hemodynamic assessment. Higher doses of mirabegron provided substantial change in 
cardiac output as well as transitorily reduction in systolic blood pressure, although we lack 
information regarding the hemodynamic response in the range of 10 to 50 µg/Kg, which might 
be of interest considering our results. Prior studies in animal models of cardiovascular disease 
have reported the use of either oral [12] or i.v. mirabegron [16, 23, 24], although the latter were 
performed mostly in rats. It might be possible that the appropriate dose was not used. Another 
explanation might be the already known interspecies differences in the cardiac effects of β3AR 
agonists [25] – i.e. mirabegron showed less cardiovascular effects in monkeys than in dogs at 
similar exposures [17], although little has been published before regarding the effect of β3AR 
agonism in pigs [9]. 
There is yet a third potential explanation. Although β3AR agonists have been 
demonstrated to protect the heart against IRI when administered either immediately before or at 
11 
 
the onset of reperfusion [8, 9], it might be possible that this single dose of mirabegron was not 
enough time “on board”. Recent experimental studies have demonstrated the importance of the 
contribution of ischemic-related injury on top of reperfusion-related injury [26–28]. Moreover, 
some therapies, such as metoprolol [29] and remote ischemic conditioning [30], have 
demonstrated to be more effective when applied long before reperfusion in the clinical setting. 
These recent findings place ischemic injury back into the focus of relevant targets for IS 
reduction and suggest that next cardioprotective therapies should be tested long before 
reperfusion and not only 5 min before its onset, as we did in the present study. 
There is yet hope for the translation of mirabegron in cardiovascular diseases. Despite 
the fact that we did not find significant differences on IS reduction and LVEF improvement 
after the use of mirabegron at the dose studied, further research testing the cardioprotective 
effect of mirabegron (or other β3AR agonists) at different doses and earlier in the course of 
ischemic time is needed in similar translational models to elucidate the potential applicability of 
this therapy in the clinical setting. Moreover, there might still be room for its translation in the 
failing heart in form of chronic treatment [11, 13, 20] – several clinical trials are currently 
recruiting patients to test the performance of mirabegron in both LV and RV failing hearts. 
There is a phase IIb, international (8 countries), placebo-controlled randomized trial 
(ISRCTN65055502) testing the effect of mirabegron to prevent or reverse the LV hypertrophic 
remodeling of patients with structural heart disease who are at risk of developing HF with 
preserved ejection fraction. The Beta3 Agonist Treatment in Chronic Pulmonary Hypertension 
Secondary to Heart Failure (SPHERE-HF, NCT02775539) is evaluating whether the use of oral 
mirabegron would improve surrogate endpoints in patients with pulmonary hypertension 
associated to heart failure. 
Limitations 
This study should be evaluated in the light of its limitations. First, although β3AR has 
been demonstrated to be present in the myocardium and endothelium of mammals[7, 17, 25], 
we did not provide evidence of their existence in our experimental model. Second, the effect of 
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mirabegron on other receptors (β1AR and β2AR) was not assessed in this study. Third, other 
non-pharmacological approaches might be used to confirm our findings, such as enhancing 
β3AR [13]. Further doses of mirabegron and different timings of administration should be tested 
to confirm that mirabegron has not the ability to be translated to AMI patients. Finally, we 
cannot ruled-out a bias in relation to the day selected for CMR imaging in the acute phase. In 
this regard, previous studies have suggested a rapid resorption of late gadolinium enhanced 
myocardium, as surrogate of IS, over the course of the first week after AMI [31–33]. 
Additionally, edema formation after IRI is very dynamic [18, 34]; and CMR estimates can vary 
according to the day of imaging or the use of cardioprotective therapies [32, 35]. However, 
given that all animals underwent the index CMR exam the same day post-IRI (i.e., day 7), 
which it is actually within the suggested time window for assessing imaging outcomes [32, 35], 
we think any potential bias would have affected all groups equally and thus did not have an 
impact on the results. 
Conclusions 
β3AR stimulation with the clinically approved mirabegron does not protect the 
myocardium against IRI in a swine model of AMI. Using cardiovascular magnetic resonance at 
days 7 and 45, no significant differences in neither infarct size nor in LVEF were observed 
between mirabegron (10 µg/kg) and placebo when administered 5 min before reperfusion. 
Taking into account previous evidence with BRL37344, these data points towards a non-class 
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Table 1. Effect of intravenous administration of mirabegron on heart rate, mean systemic artery 
pressure, mean pulmonary artery pressure and cardiac output in anesthetized pigs for doses 5. 
10, 50 and 500 µg/Kg,  
 Min 1 Min 2 Min 3 Min 4 Min 5 Min 10 Min 15 Min 20 
HR         
5 µg/Kg 0.3 (0.5) 4.4 (0.8) 2.2 (0.8) 1.1 (0.8) -0.1 (1.7) 0.2 (1.2) 1.1 (1.6) 0.5 (1.8) 
10 µg/Kg 4.8 (1.0) 7.1 (1.5) 2.9 (3.1) 2.1 (2.8) 3.2 (2.0) 3.5 (1.3) 5.0 (2.1) 5.2 (2.4) 
50 µg/Kg 17.8(4.0) 14.4(5.8) 5.5 (3.3) 3.4 (3.0) 4.0 (1.9) 3.1 (1.4) 2.4 (1.7) 1.8 (1.7) 
500 µg/Kg 48.7 (5.3) 35.9(4.3) 24.5(4.7) 20.4(3.8) 20.8(4.1) 18.4(2.1) 19.8(1.7) 17.9(1.3) 
SAP         
5 µg/Kg -4.8 (0.6) -3.6 (0.5) -2.1 (0.8) -1.3 (1.3) -0.8 (1.9) -1.5 (1.8) -1.0 (2.2) -1.7 (2.8) 
10 µg/Kg -6.6 (1.4) -2.0 (0.9) -0.5 (1.4) -0.5 (1.2) -0.8 (1.3) -1.4 (1.3) -1.0 (1.6) -1.0 (1.9) 
50 µg/Kg -9.2 (2.5) -3.2 (1.7) -0.6 (1.6) 0.0 (1.5) -0.2 (1.2) -0.8 (1.0) -0.1 (1.5) 0.4 (1.3) 
500 µg/Kg -14.6(4.0) - 7.9(2.6) -2.9 (1.2) -3.7 (1.2) -4.0 (1.4) -3.1 (1.2) -5.0 (1.3) -4.9 (1.4) 
PAP         
5 µg/Kg -1.7 (2.5) -0.8 (2.4) -3.7 (2.6) -3.6 (4.1) -3.6 (4.1) -3.6 (3.5) 1.4 (4.7) -1.6 (3.4) 
10 µg/Kg 3.1 (2.0) 0.1 (1.6) -1.9 (1.9) -1.9 (1.9) -3.9 (1.6) -5.0 (1.9) -1.0 (1.9) -2.9 (1.8) 
50 µg/Kg 1.3 (2.5) -2.9 (3.4) -4.2 (3.0) -5.0 (2.6) -5.7 (2.9) -0.8 (2.9) 1.5 (3.6) 0.1 (3.4) 
500 µg/Kg -6.1 (3.6) -11.6(2.9) -13.0(0.7) -13.2(2.3) -13.6(2.2) -8.5 (1.7) -8.5 (1.7) -9.5 (1.6) 
CO         
5 µg/Kg - - - - 4.1 (2.5) 7.5 (2.0) - 4.7 (3.0) 
10 µg/Kg - - - - 8.6 (1.1) 6.5 (3.1) - 5.3 (3.6) 
50 µg/Kg - - - - 4.5 (3.0) 5.8 (1.7) - 3.0 (2.4) 
500 µg/Kg - - - - 9.6 (5.5) 12.5(5.7) - 13.1(3.1) 
 
Results are expressed as percentage of change with respect the baseline value before drug 
administration (SD in brackets) 
HR heart rate (bpm); SAP, mean systemic arterial pressure (mmHg); PAP, mean pulmonary artery 





Table 2. Differences in hemodynamic parameters between groups during the administration of 
either placebo or mirabegron in the ongoing AMI  
 
 Mean systemic arterial 
pressure (mm Hg) 
Heart rate (bpm) 
Min Mirabegron Placebo Mirabegron Placebo 
40 a 65 (8) 70 (11) 80 (14) 97 (21) 
41 65 (9) 67 (10) 79 (13) 91 (19) 
42 63 (8) 65 (9) 79 (13) 92 (17) 
43 61 (8) 64 (8) 80 (14) 93 (15) 
44 64 (8) 68 (12) 83 (10) 95 (14) 
45 b 68 (11) 70 (11) 83 (17) 94 (15) 
 
a Just before mirabegron administration 
b Just before reperfusion 
 
Values are expressed as mean (SD). Comparisons between different time points within and 




Table 3. CMR results at day 7 
 
 Mirabegron (N=10) Placebo (N=10) p value 
LV mass (g/m2) 86.6 (14.0) 83.2 (7.8) 0.524 
LVEDV (ml/m2) 165.9 (3.9) 172.0 (23.8) 0.481 
LVESV (ml/m2) 105.7 (10.2) 113.3 (23.8) 0.370 
LVEF (%) 36.3 (3.3) 34.6 (5.7) 0.430 
Edema (g) 27.1 (6.1) 28.4 (6.8) 0.659 
Edema (%LV) 38.0 (5.6) 38.4 (5.9) 0.884 
IS (g) 24.2 (6.2) 25.2 (7.1) 0.763 
IS (%LV) 35.0 (6.0) 35.9 (7.1) 0.782 
MVO (g) 2.3 (1.6) 2.1 (1.9) 0.841 
LV mass and volumes are normalized by body surface area. 
LV, left ventricular; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular 






Table 4. CMR results at day 45 
 Mirabegron (N=8) Placebo (N=10) p value 
LV mass (g) 72.7 (8.0) 75.5 (10.7) 0.554 
LVEDV (ml/m2) 189.6 (23.7) 202.9 (43.4) 0.449 
LVESV (ml/m2) 127.9 (26.7) 143.9 (43.5) 0.377 
LVEF (%) 33.1 (5.7) 30.0 (7.0) 0.366 
IS (g) 18.1 (5.0) 21.6 (7.6) 0.300 
IS (%LV) 23.7 (6.3) 25.2 (4.5) 0.581 
LV mass and volumes are normalized by body surface area. 
 
LV, left ventricular; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular 






Fig 1. Short-term cardioprotective effect in pigs subjected to ischemia/reperfusion injury after 
pre-reperfusion administration of the β3AR mirabegron: infarct size (a) and left ventricular 
ejection fraction (b) at day 7 
 
 
 For panel a: black lines represent mean and SEM for infarct size (%) and circles represent 
individual animal data. For panel b: bar graphs represent mean and SEM for left ventricular 




Fig 2. Long-term cardioprotective effect in pigs subjected to ischemia/reperfusion injury after 
pre-reperfusion administration of the β3AR mirabegron: infarct size (a) and left ventricular 
ejection fraction (b) at day 45 
 
 
For panel a: black lines represent mean and SEM for infarct size (%) and circles represent 
individual animal data. For panel b: bar graphs represent mean and SEM for left ventricular 
ejection fraction (%). LV, left ventricle; ns, non-significant. 
 
